skin cancer
FDA approves Roche skin cancer combination
November 11, 2015Research and Development, Sales and Marketing Cotellic, FDA, Genentech, Roche, Zelboraf, cobimetinib, melanoma, skin cancer, vemurafenib
The FDA has approved the skin cancer drug Cotellic for certain forms of melanoma in combination with another Roche cancer …
Amgen skin cancer drug gets European approval
October 23, 2015Research and Development Amgen, Imlygic, melanoma, skin cancer
Amgen’s Imlygic (talimogene laherparepvec) has been approved by the scientific committee of the European Medicines Agency (EMA) for the treatment of adults …
Merck and Incyte to initiate Keytruda, epacadostat combo trial
October 15, 2015Research and Development Incyte, Merck, R&D, melanoma, phase III, skin cancer
Merck and biopharma firm Incyte are to expand their clinical collaboration to include a Phase III study evaluating the combination …
MSD’s Keytruda receives green light from NICE for NHS use
October 12, 2015Sales and Marketing MSD, Merck, NICE, keytruda, melanoma, pembrolizumab, skin cancer
The UK healthcare watchdog NICE has recommended Keytruda as a treatment for advanced skin cancer – its second endorsement of …
NICE approves Merck’s Keytruda for advanced skin cancer following ipilimumab treatment
October 7, 2015Research and Development Merck, NHS, NICE, keytruda, skin cancer
The National Institute for Health and Care Excellence (NICE) has approved Merck’s Keytruda (pembrolizumab) for treating advanced skin cancer after …
NICE recommends Keytruda for advanced skin cancer
September 7, 2015Research and Development, Sales and Marketing Merck, NICE, keytruda, skin cancer
NICE has approved Merck’s Keytruda (pembrolizumab) as a treatment for advanced skin cancer in final draft guidance for the NHS. …
Novartis and Merck skin cancer drugs move through pipeline
August 20, 2015Manufacturing and Production, Research and Development, Sales and Marketing Merck, Novartis, Odomzo, basal cell carcinoma, keytruda, melanoma, pembrolizumab, skin cancer, sonidegib
Both Novartis and Merck have hit regulatory milestones with their skin cancer drugs in the EU and the US. Novartis’ …
FDA approves Novartis drug Odomzo
July 27, 2015Sales and Marketing Novartis, Odomzo, basal cell carcinoma, skin cancer
The FDA has given the Swiss firm the go-ahead to market its drug for skin cancer. Odomzo (sonidegib, formerly LDE225) …
Opdivo launched in the UK for skin cancer
July 2, 2015Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Early Access to Medicines Scheme, MHRA, eams, melanoma, opdivo, skin cancer
Bristol-Myers Squibb has launched its cancer immunotherapy treatment Opdivo in the UK for patients with advanced skin cancer. Opdivo (nivolumab) …
EMA approves BMS’ Opdivo for advanced skin cancer
April 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer
Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …
GSK melanoma drug sees quick NICE nod
September 18, 2014Sales and Marketing Cancer, GSK, NICE, Tafinlar, Yervoy, dabrafenib, melanoma, skin cancer
NICE is recommending GlaxoSmithKline’s new melanoma treatment Tafinlar (dabrafenib) after the firm offered a discount for its medicine. In final …
Skin cancer pill shows ‘significant’ response
February 20, 2014Research and Development, Sales and Marketing LDE225, Novartis, bolt, skin cancer, smo
Novartis is celebrating after its investigational pill targeting the most common form of skin cancer met its primary endpoint in …
Eight in ten survive skin cancer
July 22, 2013Research and Development, Sales and Marketing Yervoy, Zelboraf, melanoma, skin cancer
The vast majority of men and women diagnosed with malignant melanoma are now surviving the disease, according to a new …
Melanoma: new treatments and hopes
September 19, 2011Research and Development advanced melanoma, melanoma, skin cancer
It usually starts with a subtle change of colour or shape in an existing mole. But if left undiagnosed and …
